Gilotrif (Afatinib) Reports Survival Benefit for EGFR Mutation-Positive Advanced NSCLC: Is it a Superior EGFR Inhibitor?

Article

One of the high profile presentations in the lung cancer track at ASCO 2014 was from Dr. James Yang of a pooled analysis of the LUX-Lung 3 and LUX-Lung 6 trials, each comparing Gilotrif (afatinib) to standard chemotherapy as first line treatment of EGFR mutation-positive advanced NSCLC, which for the first time demonstrated an actual survival benefit not seen in similarly designed trials with Iressa (gefitinib) or Tarceva (erlotinib).

Should We Add Avastin (Bevacizumab) to Tarceva (Erlotinib) for EGFR Mutation-Positive NSCLC?

Article

I recently had the honor of providing the expert commentary at the ASCO 2014 conference on three high impact lung cancer presentations, all on the subject of treatment options for molecularly defined populations (EGFR and ALK). I'll review the findings from these three abstracts and my perspective on each of these, starting with a very provocative presentation by Dr.